Swiss biotech startup Hedera Dx raises €14 million in its mission to improve cancer treatment options
By Patricia Allen Lausanne-headquartered Hedera Dx is pioneering the adoption of liquid biopsy in cancer treatments. The biotech startup has just raised €14 million to push forward its mission of bringing better...